Target intelligence / Profile preview

Dolichol-phosphate mannosyltransferase subunit 2 (DPM2)

Target
DPM2
Molecular classification
Enzyme regulatory protein, Subunit of enzyme complex, Other (membrane protein, ER localized)
01

Overview

Dolichol-phosphate mannosyltransferase subunit 2 (DPM2) is a highly hydrophobic, small ER membrane protein that serves as the regulatory subunit of the dolichol-phosphate-mannose (DPM) synthase complex in humans[1][3][4]. This complex is essential for the formation of dolichol-phosphate mannose, a critical glycosyl donor for various glycosylation pathways, including N-glycosylation, O-mannosylation, and GPI-anchor synthesis[1][3][4]. DPM2 anchors and stabilizes the catalytic subunit DPM1 and is essential for maintaining proper localization and activity of the complex within the endoplasmic reticulum, thereby regulating protein and lipid glycosylation[2][4]. Loss-of-function or mutation in DPM2 results in congenital disorders of glycosylation, predominantly affecting muscular and nervous system development and resulting in clinical features such as hypotonia, developmental delay, and abnormal enzyme glycosylation profiles[4]. No known drugs target DPM2 directly, and there are no established mechanisms of action for pharmacological modulation of this protein.

Other names
Dolichol phosphate-mannose biosynthesis regulatory proteinDPM synthase subunit 2Dolichol-phosphate mannose synthase subunit 2Dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunitMy026MGC21559MGC111193DPM synthase complex subunitCDG1U
02

Biological functions

Protein glycosylation (N-glycosylation, O-mannosylation, and glycosylphosphatidylinositol [GPI] anchor synthesis)Enzyme complex stabilizationRegulator of dolichol-phosphate-mannose biosynthesis
03

Disease associations

Congenital disorder of glycosylation (CDG, specifically Type Iu)Muscular dystrophy-dystroglycanopathy (via defective O-mannosylation)Other rare developmental disorders
04

Safety considerations

Deficiency or loss-of-function mutations may cause severe developmental and neuromuscular symptoms[4]No specific pharmacological safety concerns identified in the context of drug targeting, as no targeted drugs are currently known
05

Biomarkers

DPM2 mutations for Congenital Disorder of Glycosylation type Iu (CDG-Iu)Abnormal glycosylation patterns in patient samples

Beyond the preview

Go deeper on Dolichol-phosphate mannosyltransferase subunit 2 (DPM2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dolichol-phosphate mannosyltransferase subunit 2 (DPM2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call